Skip to the page

Data / Public companies / SIC 8731: Commercial physical and biological research / Inotiv, Inc.

Inotiv, Inc.: revenue, net income and total assets from its latest annual report

Updated December 5, 2025. Source: SEC Financial Statement Data Sets, filing 0001628280-25-055483.

Inotiv, Inc. reported revenue of $513.0 million, a net loss of $68.6 million and total assets of $771.1 million for the fiscal year ended September 30, 2025, in its annual report (10-K) filed with the SEC on December 5, 2025. It ranks 6th by revenue of 15 companies in SIC 8731, commercial physical and biological research.

The request: Watch Inotiv, Inc. (CIK 720154): each new SEC filing, with revenue and net income. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the annual reports that companies file with the SEC, and this page is that reading. Ask for the companies of an industry, state or city with their website, number of employees and funding added from the web, and each new annual report arrives in your sheet, CRM, Slack or agent as the SEC posts it.

SEC central index key (CIK)
720154
Industry
SIC 8731, Commercial physical and biological research
Business address (city and state)
West Lafayette, Indiana
Incorporated in
Indiana
Filer category
Accelerated filer
Fiscal year ends
September 30
Latest annual report
10-K filed December 5, 2025
Annual and quarterly reports in the data
1 annual, 3 quarterly

Financials for the fiscal year ended September 30, 2025

As filed, in US dollars. The prior year value is the comparison column in the same report.

ItemThis yearPrior yearChangeSource
Revenue$513,024,000$490,739,0004.5%sec.gov
Operating income$-30,902,000Not listedNot listedsec.gov
Net income$-68,625,000$-108,445,00036.7%sec.gov
Total assets$771,114,000$781,361,000-1.3%sec.gov
Total liabilities$635,086,000Not listedNot listedsec.gov
Stockholders' equity$136,028,000Not listedNot listedsec.gov
Cash and cash equivalents$21,741,000Not listedNot listedsec.gov

How it compares

Net margin (net income over revenue)
-13.4%
Revenue change on the prior year
4.5%
Revenue rank in SIC 8731
6th of 15
Revenue rank in Indiana
26th of 39
Revenue rank among all companies in the data
2,086th of 4,486

Companies next to it by revenue in SIC 8731

Commercial physical and biological research, from the same data.

CompanyBusiness addressRevenueNet incomeTotal assetsRevenue change
Icon PLCDublin 18, Ireland$8.25 billion$229.3 million$16.27 billion0.8%
Incyte CorpWilmington, DE$5.14 billion$1.29 billion$6.96 billion21.2%
Charles River Laboratories International, Inc.Wilmington, MA$4.02 billion$-144,338,000$7.14 billion-0.9%
Medpace Holdings, Inc.Cincinnati, OH$2.53 billion$451.1 million$1.98 billion20%
National Research CorpLincoln, NE$137.4 million$11.6 million$134.9 million-4%
Maxcyte, Inc.Rockville, MD$33 million$-44,630,000$202.5 million-14.5%
Omniab, Inc.Emeryville, CA$18.7 million$-64,779,000$300.9 million-29.3%
Foxo Technologies Inc.West Palm Beach, FL$16.4 million$-12,430,390$44.6 million304%

Public data from the US Securities and Exchange Commission. Companies are the registrants whose latest annual report (form 10-K, 20-F or 40-F) is in the SEC Financial Statement Data Sets for 2025 Q3 to 2026 Q3, filed through September 30, 2026. Figures are for the whole fiscal year of that report, in US dollars, as the company filed them in XBRL: SpecStream does not adjust them. The SEC does not guarantee the data sets, and they do not replace the filings. Revenue is the revenue tag the company used; banks and funds often use none. Combined totals add each company once and can include a parent and its subsidiary that both file. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.